scispace - formally typeset
Open AccessJournal ArticleDOI

EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study

Reads0
Chats0
TLDR
In smokers not intending to quit, the use of e-cigarettes, with or without nicotine, decreased cigarette consumption and elicited enduring tobacco abstinence without causing significant side effects.
Abstract
Background: Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide. Users report buying them to help quit smoking, to reduce cigarette consumption, to relieve tobacco withdrawal symptoms, and to continue having a ‘smoking’ experience, but with reduced health risks. Research on e-cigarettes is urgently needed in order to ensure that the decisions of regulators, healthcare providers and consumers are based on science. Methods ECLAT is a prospective 12-month randomized, controlled trial that evaluates smoking reduction/abstinence in 300 smokers not intending to quit experimenting two different nicotine strengths of a popular e-cigarette model (‘Categoria’; Arbi Group Srl, Italy) compared to its non-nicotine choice. GroupA (n=100) received 7.2 mg nicotine cartridges for 12 weeks; GroupB (n=100), a 6-week 7.2 mg nicotine cartridges followed by a further 6-week 5.4 mg nicotine cartridges; GroupC (n=100) received no-nicotine cartridges for 12 weeks. The study consisted of nine visits during which cig/day use and exhaled carbon monoxide (eCO) levels were measured. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed. Results: Declines in cig/day use and eCO levels were observed at each study visits in all three study groups (p,0.001 vs baseline), with no consistent differences among study groups. Smoking reduction was documented in 22.3% and 10.3% at week-12 and week-52 respectively. Complete abstinence from tobacco smoking was documented in 10.7% and 8.7% at week-12 and week-52 respectively. A substantial decrease in adverse events from baseline was observed and withdrawal symptoms were infrequently reported during the study. Participants’ perception and acceptance of the product under investigation was satisfactory. Conclusion: In smokers not intending to quit, the use of e-cigarettes, with or without nicotine, decreased cigarette consumption and elicited enduring tobacco abstinence without causing significant side effects. Trial Registration: ClinicalTrials.gov NCT01164072

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

A systematic review of randomized controlled trials and network meta-analysis of e-cigarettes for smoking cessation.

TL;DR: In this article, the authors compared the effectiveness of nicotine e-cigarettes for smoking cessation with licensed nicotine replacement therapies (NRT) and nicotine-free based control conditions by using network meta-analysis (NMA).
Journal ArticleDOI

Efficiency and adverse events of electronic cigarettes: A systematic review and meta-analysis (PRISMA-compliant article).

TL;DR: E-cigarettes are moderately effective with regard to smoking reduction and smoking cessation, and eCO levels are unreliable for evaluating the efficacy of e-cigarettes.
Journal ArticleDOI

Efficacy of Electronic Cigarettes for Smoking Cessation

TL;DR: There is limited evidence for the effectiveness of e-cigarettes in smoking cessation; however, there may be a place in therapy to help modify smoking habits or reduce the number of cigarettes smoked.
Journal ArticleDOI

Mining social media data for opinion polarities about electronic cigarettes

TL;DR: The organic—against tweets raised public awareness of potential health risks and could aid in preventing non-smokers, adolescents and young adults from using e-cigarettes.
Journal ArticleDOI

Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation

TL;DR: Mean continuous abstinence rates up to 52 weeks from initiation of smoking cessation attempts in clinical trials can be modelled using simple power functions for placebo, nicotine replacement therapy and bupropion and a logarithmic function for varenicline.
References
More filters
Journal ArticleDOI

An inventory for measuring clinical anxiety: psychometric properties.

TL;DR: Un nouvel inventaire auto-administre destine a mesurer l'anxiete pathologique, le «Beck Anxiety Cheklist» (BAI) est decrit, evalue et compare au «Hamilton Anxiety Rating Scale» (test avec lequel des correlations moderees sont trouvees).

Treating Tobacco Use and Dependence: 2008 Update

TL;DR: The Panel recognized that variations in study inclusion criteria sometimes were warranted and made recommendations based on evidence, which occurred with topics such as tobacco dependence treatment in specific populations, tailoring interventions, and cost-effectiveness of Tobacco dependence treatment.
Journal ArticleDOI

Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire.

TL;DR: The findings indicate that the FTQ correlates with other proposed measures of nicotine dependence (carbon monoxide, nicotine, and cotinine levels), and the connection between FTQ scores and withdrawal symptoms is weak.
Journal ArticleDOI

Treating tobacco use and dependence.

TL;DR: This month, the Clinical Practice Guideline (CPG) column reviews the recently published guideline, Treating Tobacco Use and Dependence, available in a quick reference format and more comprehensive clinician's guide that includes detailed information on the methodology and references used to develop the guidelines.
Related Papers (5)